Induction of apoptosis in K562 cells by dicyclohexylammonium salt of hyperforin through a mitochondrial-related pathway

• Published in: Chemico-biological interactions 2011-04, Vol.190 (2), p.91-101
• Main Authors: Liu, Jin-Yun, Liu, Zhong, Wang, Dong-Mei, Li, Man-Mei, Wang, Shao-Xiang, Wang, Rui, Chen, Jian-Ping, Wang, Yi-Fei, Yang, De-Po
• Format: Article
• Language: English
• Subjects: antineoplastic agents; Antineoplastic Agents - chemistry; Antineoplastic Agents - toxicity; Antitumor activity; Apoptosis; Caspase 3 - metabolism; Caspase 8 - metabolism; Caspase 9 - metabolism; caspases; cell growth; condensation; Cyclin-Dependent Kinase Inhibitor p27 - metabolism; cytochrome c; Cytochromes c - metabolism; cytotoxicity; DNA Fragmentation; flowering; G1 Phase; Humans; hyperforin; Hyperforin derivatives; Hypericum - chemistry; Hypericum perforatum; inhibitory concentration 50; interphase; K562 Cells; membrane potential; Mitochondria - drug effects; Mitochondria - metabolism; myeloid leukemia; Phloroglucinol - analogs & derivatives; Phloroglucinol - chemistry; Signal Transduction; Terpenes - chemistry; Terpenes - toxicity; therapeutics; Tumor Suppressor Protein p53 - metabolism
• ISSN: 0009-2797; 1872-7786
• DOI: 10.1016/j.cbi.2011.02.026

Hyperforin is an abundant phloroglucinol-type constituent isolated from the extract of the flowering upper portion of the plant Hypericum perforatum L. The dicyclohexylammonium salt of hyperforin (DCHA-HF) has exhibited antitumor and antiangiogenic activities in various cancer cells. Here, the antitumor effects of DCHA-HF on the chronic myeloid leukemia K562 cell line were investigated for the first time. DCHA-HF exhibited dose- and time-dependent inhibitory activities against K562 cells, with IC 50 values of 8.6 and 3.2 μM for 48 h and 72 h of treatment, respectively, which was more effective than that of the hyperforin. In contrast, little cytotoxic activity was observed with DCHA-HF on HUVECs. DCHA-HF treatment resulted in induction of apoptosis as evidenced from DNA fragmentation, nuclear condensation and increase of early apoptotic cells by DAPI staining analysis, TUNEL assay and Annexin V-FITC/PI double-labeled staining analysis, respectively. Moreover, DCHA-HF elicited dissipation of mitochondrial transmembrane potential that commenced with the release of cytochrome c through down-regulation of expression of anti-apoptotic proteins and up-regulation of expression of pro-apoptotic proteins. DCHA-HF treatment induced activation of the caspase 3, 8, and 9 cascade and subsequent PARP cleavage, and DCHA-HF-induced apoptosis was significantly inhibited by caspase inhibitors. Treated cells were arrested at the G1 phase of the cell cycle and the expression of p53 and p27 Kip1, two key regulators related to cell cycle and apoptosis, was up-regulated. These results suggest that DCHA-HF inhibits K562 cell growth by inducing caspase-dependent apoptosis mediated by a mitochondrial pathway and arresting the cell cycle at the G1 phase. Therefore, DCHA-HF is a potential chemotherapeutic antitumor drug for chronic myeloid leukemia therapy.